Newborn infants have little or no secretory IgA (SIgA) at birth. Earlier studies suggest that premature infants do not significantly differ from term babies in their rate of acquisition of SIgA.
Lactiga’s secretory IgA replacement therapy for compromised immune function receives NIAID funding
Lactiga Inc. has been awarded a multiyear grant by the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate the advancement of the company’s lead asset, LCTG-001, a secretory ...
This funding will accelerate the advancement of Lactiga’s lead asset, LCTG-001—the first-ever secretory IgA (sIgA) mucosally-targeted replacement therapy for patients with compromised immune ...
Upper respiratory tract infection (URTI) is a common illness. Recent studies have shown that suppression of secretory immunoglobulin A (SIgA) is associated with increased incidence of URTI. Objective: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback